A.V. GANEEVA, R.I. GABIDULLINA, S.D. MAYANSKAYA

Kazan State Medical University” of the Ministry of Health of the Russian Federation, Kazan

 Contact details:

Ganeeva A.V. – Assistant of the Department of Obstetrics and Gynecology named after Professor V.S. Gruzdev

Address: 49 Butlerova St., 420012, Kazan, tel. +7-917-253-15-78, e-mail: a.v.ganeeva@gmail.com

The aim of the study was to evaluate the effectiveness of low doses of aspirin for the prevention of preeclampsia in women at risk with high long-term blood pressure variability.

Material and methods. The work is based on the results of a survey of 97 women who were at risk for the development of preeclampsia (PE). The participants were divided into groups according to long-term blood pressure variability (BP) and the ability to take low-dose aspirin to prevent the development of PE. During the observation, an assessment of pregnancy outcomes for the mother and the newborn was made, as well as the dynamics of blood pressure variability during the use of aspirin.

Results. The incidence of PE in pregnant women with high BP variability was 48%. The use of low doses of aspirin in pregnant women with high BP variability led to a decrease in the frequency of PE by 5.8 times: from 48 to 8.3% (p‹0.05). At the same time, a decrease in blood pressure variability was noted against the background of aspirin prophylaxis. Also, positive impact on the outcomes of pregnancy and childbirth for newborns was revealed.

Conclusions. Taking aspirin at a dosage of 75 mg/day from 14 to 36 weeks of pregnancy is an effective measure for the prevention of preeclampsia in women with a high risk of its development and high long-term variability of blood pressure.

Key words: blood pressure variability, preeclampsia, aspirin.

 (For citation: Ganeeva A.V., Gabidullina R.I., Mayanskaya S.D. Effectiveness of low doses of aspirin in the prevention of pre-eclampsia in pregnant women at risk with high blood pressure variability. Practical medicine. 2019. Vol. 17 №4, P. 43-47)

REFERENCES

1. Olenev A.S., Novikova V.A., Radzinskiy V.E. World conceptual approaches to reducing maternal mortality. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie, 2018, vol. 6, no. 3, pp. 5-17 (in Russ.).
2. Rolnik D.L., Wright D., Poon L.C. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound in Obstetrics & Gynecology, 2017, vol. 50, no. 4, pp. 492–495.
3. Panagodage S., Yong H.E., Da Silva Costa F. et al. Low-dose acetylsalicylic acid treatment modulates the production of cytokines and improves trophoblast function in an in vitro model of early-onset preeclampsia. Am J Pathol, 2016, vol. 186, no. 12, rr. 3217–3224.
4. Widmer M., Cuest S.V., Khan K. Accuracy of angiogenic biomarkers for predicting preeclampsia: An observational study. Pregnancy Hypertension: An International Journal of Women’s Cardiovascular Health, 2015, vol. 5, no. 1, p. 50.
5. Pedroso M., Palmer K., Hodges R.J. et al. Uterine Artery Doppler in Screening for Preeclampsia and Fetal Growth Restriction. Rev Bras Ginecol Obstet, 2018, vol. 40, no. 5, pp. 287-293.
6. Ostroumova O.D. The value of blood pressure variability in clinical practice. Possibilities of amlodipine in reducing intravisit variability of blood pressure (according to the results of the Russian program «Variation»). Sistemnye gipertenzii, 2014, vol. 1, no. 11, pp. 11-16 (in Russ.).
7. Mayanskaya S.D., Ganeeva A.V., Gabidullina R.I. Variability of blood pressure in pregnant women with risk factors for preeclampsia. Kazanskiy meditsinskiy zhurnal, 2019, no. 3, pp. 426-433 (in Russ.).
8. Adamyan L.V., Artymyuk N.V., Bashmakova N.V. et al. Gipertenzivnye rasstroystva po vremya beremennosti, v rodakh i poslerodovom periode. Preeklampsiya. Eklampsiya [Hypertensive disorders during pregnancy, childbirth and the postpartum period. Preeclampsia Eclampsia]. Klinicheskie rekomendatsii. Protokol lecheniya, 2016. 72 p.